Literature DB >> 14503667

In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes.

Jin Shimakura1, Naoko Tani, Yoshiko Mizuno, Setsuko Komuro, Hiroshi Kanamaru.   

Abstract

In vitro metabolism studies were conducted to assess drug-drug interactions between perospirone, an antipsychotic agent, and concomitantly administered drugs--biperiden, flunitrazepam, haloperidol, and diazepam--using human liver microsomes. The metabolism of perospirone in the presence of 100 microg/ml drugs was decreased to 45-73% of that in their absence, whereas no effects were observed with any of the drugs at 1 microg/ml or lower. The effects of perospirone on the metabolism of concomitantly administered drugs were also assessed, and no inhibitory effect was observed. Thus, the metabolism of perospirone and concomitantly administered drugs did not demonstrate any marked mutual inhibition in the human liver microsomes. On the other hand, the perospirone metabolism was markedly reduced by ketoconazole indicating a major role for CYP 3A4. Based on the inhibition constant (Ki) for perospirone metabolism and the plasma unbound concentration of ketoconazole, in vivo perospirone clearance was estimated to be reduced to 64-90% of the control level. Thus careful attention should be paid to the possibility of increase in unchanged perospirone concentration when perospirone is co-administered with drugs that are known as CYP3A4 inhibitors, including macrolide antibiotics and other imidazole antifungals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503667     DOI: 10.1007/BF03190869

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  In vitro metabolism of perospirone in rat, monkey and human liver microsomes.

Authors:  Yoshiko Mizuno; Naoko Tani; Setsuko Komuro; Hiroshi Kanamaru; Iwao Nakatsuka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

2.  Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam.

Authors:  A Grahnén; P Wennerlund; B Dahlström; S A Eckernäs
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

Authors:  K Ito; T Iwatsubo; S Kanamitsu; K Ueda; H Suzuki; Y Sugiyama
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

4.  CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.

Authors:  L M Hesse; K Venkatakrishnan; L L von Moltke; R I Shader; D J Greenblatt
Journal:  Drug Metab Dispos       Date:  2001-02       Impact factor: 3.922

5.  The pharmacokinetics of ketoconazole after chronic administration in adults.

Authors:  N R Badcock; F D Bartholomeusz; D B Frewin; L N Sansom; J G Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Determination of benzodiazepine anticonvulsants in plasma by high-performance liquid chromatography.

Authors:  R J Perchalski; B J Wilder
Journal:  Anal Chem       Date:  1978-04       Impact factor: 6.986

7.  Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.

Authors:  L P Pan; P Wijnant; C De Vriendt; M T Rosseel; F M Belpaire
Journal:  Br J Clin Pharmacol       Date:  1997-12       Impact factor: 4.335

8.  Interaction study between remoxipride and biperiden.

Authors:  W Yisak; L Farde; C von Bahr; L B Nilsson; G Fredriksson; S Ogenstad
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 9.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

10.  Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner.

Authors:  T Yasumori; K Nagata; S K Yang; L S Chen; N Murayama; Y Yamazoe; R Kato
Journal:  Pharmacogenetics       Date:  1993-12
View more
  1 in total

1.  Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells.

Authors:  Yan-Gang Zhou; Kun-Yan Li; Huan-De Li
Journal:  Eur J Clin Pharmacol       Date:  2008-05-14       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.